Gossamer Bio, Inc. (GOSS)
D
Pipeline Grade
Financial Position (from SEC Filings)
$41.0M
Cash & Equivalents
$38.7M
Quarterly Burn Rate
3 mo
Est. Cash Runway
$83M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-01 | Phase3 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06274801 | Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) | PHASE3 | Active Not Recruiting | 316 |
| NCT04816604 | Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) | PHASE2 | Active Not Recruiting | 74 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-05 | 8-K | Gossamer Bio, Inc. (GOSS) (CIK 0001728117) - 8-K | EDGAR |